Lundbeck breathes life into stranded molecule to treat new diseases

Drug candidate LU AG06466, which failed as a treatment for Tourette's, is the center of attention in two new phase I trials Lundbeck has launched this summer.

Photo: Lundbeck / PR

Lundbeck means business in picking drug candidate LU AG06466 back up again. The Danish pharmaceutical company is testing the drug in three phase I trials. In March 2020, it failed as a treatment for Tourette's syndrome in a phase II trial.

In September, the company started recruiting people for testing the drug candidate as a treatment for post-traumatic stress disorder (PTSD), and this summer the company has started setting up two more trials with the drug for treating multiple sclerosis and fibromyalgia, according to database Clinical Trials.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs